Past, Present, and Future of Pharmacologic Therapy in Obesity

José E. Rodríguez, Kendall M. Campbell

Research output: Contribution to journalReview articlepeer-review


Medications for obesity management can be divided into 4 groups: antidepressants (naltrexone/bupropion), stimulants (phentermine, phendimetrazine, diethylpropion, phentermine/topiramate), fat blockers (orlistat), and diabetes medications (liraglutide). Each group has specific therapeutic effects, adverse effects, and costs. Two medications are indicated for long-term use in obesity: lorcaserin and orlistat. Other available medications are for short-term use. High cost makes many of these medications inaccessible for underserved and poor patients. Because of misuse potential, many obesity medications are also classified as controlled substances. There are no medications currently approved for use in pregnant or lactating women.

Original languageEnglish (US)
Pages (from-to)61-67
Number of pages7
JournalPrimary Care - Clinics in Office Practice
Issue number1
StatePublished - Mar 1 2016
Externally publishedYes


  • Antidepressants
  • Fat blockers
  • Obesity
  • Pharmacology treatment
  • Stimulants

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Past, Present, and Future of Pharmacologic Therapy in Obesity'. Together they form a unique fingerprint.

Cite this